GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acepodia Inc (ROCO:6976) » Definitions » Capex-to-Revenue

Acepodia (ROCO:6976) Capex-to-Revenue : 0.00 (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Acepodia Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Acepodia's Capital Expenditure for the six months ended in Jun. 2023 was NT$-44.43 Mil. Its Revenue for the six months ended in Jun. 2023 was NT$0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


Acepodia Capex-to-Revenue Historical Data

The historical data trend for Acepodia's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acepodia Capex-to-Revenue Chart

Acepodia Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
- - - 10.81

Acepodia Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial - - - - -

Competitive Comparison of Acepodia's Capex-to-Revenue

For the Biotechnology subindustry, Acepodia's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acepodia's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acepodia's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Acepodia's Capex-to-Revenue falls into.



Acepodia Capex-to-Revenue Calculation

Acepodia's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-179.37) / 16.593
=10.81

Acepodia's Capex-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-44.425) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acepodia  (ROCO:6976) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Acepodia Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Acepodia's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Acepodia (ROCO:6976) Business Description

Traded in Other Exchanges
N/A
Address
17th floor-12, Number 99, Section 1, Xintai 5th Road, Xizhi District, New Taipei, TWN, 22175
Acepodia Inc is a clinical stage biotechnology company engaged to develop innovative highly effective first-in-class cell therapies by using Antibody-Cell Conjugation platform technology for cancer that are broadly accessible for patients.

Acepodia (ROCO:6976) Headlines

No Headlines